media – Page 13 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

It is better to look at the long-term situation

October is coming to an end, and the third quarter “exam” of the innovative drug industry will also come to an end. From the surface, although the entire industry is still turbulent, new drug research and development is crowded with “involution”, commercialization challenges are numerous, and the capital winter is still spreading, but from the performance point of view, the situation does not seem to be as bad as imagined. On the one hand, as the product strength and commercialization capabilities of leading innovative pharmaceutical companies are constantly confirmed, their revenue continues to grow at a high rate and their profitability is enhanced; on the other hand, more and more pharmaceutical companies have also achieved phased results in cost control in reducing costs and increasing efficiency. The resonance of the two major factors has further expanded the “loss reduction” camp. Various signs indicate that in the cold winter after the ...
- Source: drugdu
- 56
- November 2, 2024
Domestic TCE polyclonal antibodies are “surging”

MNCs are hunting for domestic molecules and have already involved the field of TCE polyclonal antibodies. On October 29, GlaxoSmithKline announced the acquisition of Enmu Bio’s CD19 and CD20 targeted T cell engager CMG1A46, including a $300 million advance payment and $550 million in potential milestone payments. Not long ago in August, Merck also bought Tongrun Bio’s CD3xCD19 bispecific antibody CN201 with a down payment of $700 million and a milestone payment of $600 million. The direction of the giants is also relatively consistent: betting on the autoimmune market. At present, the core “battlefield” of TCE polyclonal antibodies is tumors. TCE polyclonal antibodies are relatively special. One end (or two ends) is connected to TAA (tumor-associated antigen) to locate tumor cells, and the other end is connected to the CD3 epitope of T cells to activate T cells and exert the tumor-killing effect of T cells. In the field of ...
- Source: drugdu
- 53
- November 2, 2024
Medici Globalization Strategy Accelerates, Overseas Business Reaches New Heights

On the evening of October 30, Medici released its Q3 2024 report. In the third quarter, the company achieved operating revenue of 280 million yuan, a year-on-year decrease of 9.83%, and a net profit loss attributable to shareholders of approximately 58.44 million yuan. The company attributed this primarily to changes in the investment and financing environment for biomedicine during the reporting period, intensified industry competition, declining order prices, delays in executing some orders, and a decrease in gross profit margins. Domestic and international laboratory progress is promising, deepening the global strategic layout. As a pioneer of China’s Contract Research Organizations (CRO), Medici has maintained a forward-looking approach since its inception, adhering to a dual-market development strategy that encompasses both domestic and international markets. Its overseas operations span many regions, including the United States, Europe, Japan, and South Korea, and the company has established deep cooperative relationships with internationally renowned pharmaceutical ...
- Source: drugdu
- 54
- November 2, 2024
Ensuring patients’ peace of mind through the stable operation of medical insurance institutions and enterprises – the medical insurance department is intensifying efforts to introduce incremental policies to serve and safeguard the overall development

Since the beginning of this year, the medical insurance department has firmly established the development concept centered on the people, adhered to the general tone of seeking progress while maintaining stability, grasped the key points, took the initiative, effectively implemented existing policies, strengthened the introduction of incremental policies, effectively grasped the bottom line of people’s livelihood, and served and guaranteed the overall macroeconomic development. Ensure patients can seek medical treatment with peace of mind and continue to promote cost reduction and efficiency improvement in medication consumption From January to September, medical insurance settled 6.916 billion people, a year-on-year increase of 19.3%, including 4.898 billion outpatient visits, an increase of 25% compared to the same period in 2023, effectively ensuring the demand for outpatient medical treatment. Deepen the reform of employee medical insurance outpatient mutual assistance guarantee, expand the scope of personnel and fund use in personal account mutual assistance, and ...
- Source: drugdu
- 57
- November 2, 2024
The first patient enrolled in the Phase III clinical trial of first-line treatment for biliary tract tumors using the head to head valumab regimen and the Ivo Western regimen

Recently, Kangfang Biotechnology (9926. HK) announced the completion of the first patient enrollment in a randomized, controlled, multicenter, registered Phase III clinical trial (HARMONI-GI-01/AK112-309) of its independently developed PD-1/VEGF bispecific antibody combination regimen with Ivexil and a comparison with Valiumab (PD-L1) combination regimen for first-line treatment of advanced biliary malignancies (BTC). Research on AK112-309 The HARMONI-GI-01/AK112-309 study was conducted by renowned domestic liver and gallbladder tumor experts, Professor Zhou Jian from Zhongshan Hospital affiliated with Fudan University and Professor Zheng Tongsen from Harbin Medical University Cancer Hospital, as co principal investigators. The endpoint of the study was overall survival (OS). The HARMONI-GI-01/AK112-309 study is the sixth registered phase III clinical trial conducted by Ecovaci, using PD-1/L1 monoclonal antibodies as control drugs. It reflects the company’s determination and confidence in iterating the current tumor immunotherapy landscape and establishing better global cancer standard treatments. It also demonstrates the ability of Kangfang Biotech ...
- Source: drugdu
- 47
- November 2, 2024
Layoffs, Business Transfer

Recently, foreign media reported that Philips Wellcome has notified its suppliers that it plans to outsource the manufacturing operations of its factories in Murrysville and New Kensington, Pennsylvania to Thailand. It is reported that this is based on a letter sent by Philips subsidiary to suppliers in June, stating that contractor manufacturer Kimball Electronics will take over this work at its Thailand factory in the next two years. The Pittsburgh Post reported that this move will result in the reduction of hundreds of job positions. It is understood that the two manufacturing plants in Pennsylvania are part of Philips Wellcome’s operations and are subject to a consent order from the FDA and the US Department of Justice, which involves the company’s large-scale recall of continuous positive airway pressure (CPAP) and bi level positive airway pressure (BiPAP) ventilators in Class I. Philips stated in a statement to the Pittsburgh Post that ...
- Source: drugdu
- 55
- November 2, 2024
Mesenchymal stromal cells (non stem cells) have been approved by the FDA for clinical trials in the treatment of acute ischemic stroke

The world’s first allogeneic adipose derived mesenchymal stromal cells (AD MSCs) drug (NR-20201) developed by Tianshi Pharmaceutical Group Co., Ltd. for the treatment of acute ischemic stroke received clinical trial approval from the US Food and Drug Administration (FDA) on October 26, 2024. It is reported that in the process of developing NR-20201, the company used artificial intelligence to analyze single-cell transcriptomics, cell life trajectories, and fate outcomes [1,2], confirming that the AD MSCs produced by Tasly’s standard preparation process are mesenchymal stromal cells rather than mesenchymal stem cells. Based on the difference between stromal cells and stem cells, this product has unique identification criteria and a mechanism of action different from stem cells. This product selects a suitable treatment time window based on the patient’s condition, promoting effective homing of cells after intravenous infusion. After cell homing, it works synergistically with endothelial cells to activate vascular regeneration and functional ...
- Source: drugdu
- 50
- November 2, 2024
AI+Gene Therapy | Dyno partners with Roche, with a prepayment of $50 million and a total value exceeding $1 billion

On October 24, 2024, Dyno Therapeutics, a gene technology company that utilizes artificial intelligence for in vivo gene delivery, announced its second research collaboration with Roche to jointly develop the next generation of adeno-associated virus (AAV) vectors for gene therapy targeting neurological diseases.Dyno and Roche previously announced a research collaboration and licensing agreement in October 2020 for neurological disorders and liver targeted therapies. According to this new collaboration agreement, Dyno Therapeutics will provide Roche with more opportunities to utilize the company’s leading platform and sequence design technology in the field to achieve in vivo gene delivery. The existing gene therapies mainly use a small amount of naturally occurring AAV vectors, which have problems such as low delivery efficiency, pre-existing immunity, and manufacturability. To overcome these challenges, Dyno took the lead in applying artificial intelligence and high-throughput in vivo data acquisition technology to engineer the AAV virus capsid, in order to ...
- Source: drugdu
- 54
- November 1, 2024
The 3rd Analysis and Testing Summit Forum and Academic Annual Conference of the Journal of Analysis and Testing in 2024 grandly opened in Guangzhou

From September 21st to 25th, 2024, the “2024 Analysis and Testing Summit Forum and Annual Conference of Analysis and Testing Academic Newspaper” jointly organized by the Journal of Analysis and Testing, the Testing and Analysis Research Institute of Guangdong Academy of Sciences (Guangzhou Analysis and Testing Center, China), the China Association for Analysis and Testing, and the Guangdong Association for Analysis and Testing was held at the Nikko Hotel in Guangzhou. This forum focuses on innovation and development in the field of analysis and testing, attracting more than 1000 academicians, scholars, and business representatives from various cutting-edge fields such as environment and health, life analysis, food safety, new technologies, and scientific instrument development; By adopting a combination of online and offline modes, we have successfully attracted over 10000 online viewers, breaking down geographical boundaries and expanding our audience base. On the morning of the 23rd, the forum was officially opened. ...
- Source: drugdu
- 76
- November 1, 2024
Total investment is 500 million yuan! The first integrated intelligent factory project for synthetic biology CDMO full process in Jiangsu Province has been launched

On the morning of October 22nd, Fenghuang Town successfully signed a contract with Suzhou Womei Biotechnology Co., Ltd. for the “Womei Biosynthetic CDMO Factory” project, which is the first project to settle in Feixiang Pharmaceutical Industrial Park since its approval. Teng Xiaonuo, General Manager of Suzhou Womei Biotechnology Co., Ltd., Professor Ren Guobin, Vice Dean of the Research Institute of East China University of Science and Technology, Wang Weimin, Secretary of the Phoenix Town Party Committee, Tian Wenhua, Deputy Secretary of the Town Party Committee and Mayor, Ji Xiaoyang, Deputy Secretary of the Town Party Committee, and others participated in the signing. This project is based on leading process control and intelligent manufacturing technologies at home and abroad, and aims to establish a green intelligent factory that integrates consumables, process engineering, and equipment. It balances production efficiency and cost control, and strives to build a first-class synthetic biology CDMO industry ...
- Source: drugdu
- 66
- November 1, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.